摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,3-dihydropyrrolo<1,2,3-de><1,4>benzothiazine | 141650-35-3

中文名称
——
中文别名
——
英文名称
2,3-dihydropyrrolo<1,2,3-de><1,4>benzothiazine
英文别名
2,3-dihydro-pyrrolo<1,2,3-de>-1,4-benzothiazine;2,3-dihydro-[1,4]thiazino[2,3,4-hi]indole;3,4-dihydro-5-thia-2a-aza-acenaphthalene;2,3-Dihydropyrrolo[1,2,3-de]-1,4-benzothiazine;9-thia-1-azatricyclo[6.3.1.04,12]dodeca-2,4(12),5,7-tetraene
2,3-dihydropyrrolo<1,2,3-de><1,4>benzothiazine化学式
CAS
141650-35-3
化学式
C10H9NS
mdl
——
分子量
175.254
InChiKey
SIMNGPMCJKJAJU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    361.1±21.0 °C(Predicted)
  • 密度:
    1.31±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    30.2
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

点击查看最新优质反应信息

文献信息

  • Agents and methods for the treatment of proliferative diseases
    申请人:——
    公开号:US20030229026A1
    公开(公告)日:2003-12-11
    The present invention provides selective kinase inhibitors of formula (I). 1
    这项发明提供了式(I)的选择性激酶抑制剂。
  • Agents and method for the treatment of proliferative diseases
    申请人:——
    公开号:US20030092676A1
    公开(公告)日:2003-05-15
    1 The present invention provides selective kinase inhibitors of formula (I).
    本发明提供了式(I)的选择性激酶抑制剂。
  • Tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivatives as cannabinoid cb1 receptor agonists
    申请人:Adam-Worrall Julia
    公开号:US20070088025A1
    公开(公告)日:2007-04-19
    The invention relates to tricyclic 1-[(in-dol-3-yl)carbonyl]piperazine derivative having the general Formula (I) wherein X is CH 2 , O or S; R represents 1-3 substituents independently selected from H, (C 1-4 )alkyl, (C 1-4 )alkyloxy and halogen; R 1 is (C 5-8 )cycloalkyl; R 2 is H or (C 1-4 )alkyl; R 3 , R 3 ′, R 4 ′, R 4 ′, R 5 , R 5 ′ and R 6 ′ are independently hydrogen or (C 1-4 )-alkyl, optionally substituted with (C 1-4 )alkyloxy, OH or halogen; R 6 is hydrogen or (C 1-4 )alkyl, optionally substituted with (C 1-4 )alkyloxy, OH or halogen; or R 6 forms together with R 7 a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O and S; R 7 forms together with R 6 a 4-7 membered saturated heterocydic ring, optionally containing a further heteroatom selected from O and S; or R 7 is H, (C 1-4 )alkyl or (C 3-5 )cycloalkyl, the alkyl groups being optionally substituted with OH, halogen or (C 1-4 )alkyloxy; or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivatives, and to the use of these derivatives in the treatment of pain, such as peri-operative pain, chronic pain neuropathic pain, cancer pain, and pain and spasticity associated with multiple sclerosis.
    本发明涉及三环1-[(吲哚-3-基)羰基]哌嗪衍生物,其具有通式(I),其中X为CH2、O或S;R代表1-3个取自H、(C1-4)烷基、(C1-4)烷氧基和卤素的取代基;R1为(C5-8)环烷基;R2为H或(C1-4)烷基;R3、R3'、R4'、R4'、R5、R5'和R6'独立地为氢或(C1-4)烷基,可选地被(C1-4)烷氧基、OH或卤素取代;R6为氢或(C1-4)烷基,可选地被(C1-4)烷氧基、OH或卤素取代;或R6与R7形成4-7成员饱和杂环环,可选地包含进一步的选自O和S的杂原子;R7与R6a形成4-7成员饱和杂环环,可选地包含进一步的选自O和S的杂原子;或R7为H、(C1-4)烷基或(C3-5)环烷基,烷基基团可选地被OH、卤素或(C1-4)烷氧基取代;或其药学上可接受的盐。本发明还涉及含有上述三环1-[(吲哚-3-基)羰基]哌嗪衍生物的制药组合物,以及在治疗疼痛,如围手术期疼痛、慢性疼痛、神经病性疼痛、癌症疼痛和与多发性硬化症相关的疼痛和痉挛中使用这些衍生物的用途。
  • (Indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor
    申请人:Adam-Worrall Julia
    公开号:US20070142446A1
    公开(公告)日:2007-06-21
    Disclosed herein are indole derivatives of the formula (I) wherein each of the substitutents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the indole derivatives and use of the derivatives for the treatment of pain.
    本文揭示了公式(I)的吲哚衍生物,其中每个取代基的定义如规范和要求所述。还揭示了含有这些吲哚衍生物的药物组合物,并且这些衍生物可用于治疗疼痛。
  • [EN] INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)<br/>[FR] INHIBITEURS DE LA KINASE 7 DÉPENDANTE DES CYCLINES (CDK7)
    申请人:MARINEAU JASON J
    公开号:WO2018013867A8
    公开(公告)日:2018-11-15
查看更多